Introduction {#s1}
============

Insulin influences energy metabolism and growth, which are mostly mediated by the activation of the PI3K/Akt pathway and the Ras/MAPK pathway, respectively. The brain is one of the major targets of insulin. Through binding with its specific receptor and activating its downstream signaling, insulin exhibits central neuromodulatory functions. For example, insulin has been reported to be involved in the regulation of synaptic formation, learning and memory, cognition, neuronal stem cell activation, and neuronal apoptosis ([@B28]). Therefore, insulin deficiency or impairment of insulin signaling (namely, insulin resistance) in the central nervous system (CNS) can result in brain disorders.

In the past decades, growing evidence from clinical and laboratory studies has linked insulin resistance to neurodegenerative disorders, such as Parkinson's disease (PD) and Alzheimer's disease (AD) ([@B23]; [@B1]; [@B28]). Insulin resistance can indeed affect tau phosphorylation, the metabolism of the amyloid precursor protein, and clearance of beta-amyloid (Aβ) from the brain, thus contributing to the development of neurodegenerative diseases ([@B19]).

Icariin, a major bioactive component extracted from plants of the *Epimedium* genus ([@B12]), has been shown to ameliorate insulin resistance in skeletal muscle cells ([@B6]; [@B10]; [@B13]) and restore impaired hypothalamic insulin signaling in the rats with chronic unpredictable mild stress ([@B18]). Currently, icariin has been found to evoke the neuroprotective effects *in vivo*. Indeed, icariin may improve learning and memory dysfunction, as well as synaptic and cognitive deficits, in the AD mice ([@B29]; [@B3]; [@B24]). In the PD mice, icariin has also been reported to reduce dopaminergic neuronal loss and neuroinflammation ([@B30]; [@B37]). However, the molecular mechanisms underlying the effects of icariin on neuronal insulin resistance remain elusive, although the neuroprotective properties of icariin in PD mice were reported to be associated with its regulation of the PI3K/Akt and the MEK/ERK signaling pathways ([@B4]).

In the present study, we found that icariin significantly attenuated Aβ-induced insulin resistance in human neuroblastoma SK-N-MC cells. We also confirmed that the enhancement of proteasome activity by icariin treatment contributed to the degradation of the phosphatase and tensin homologue deleted on chromosome 10 (PTEN). These findings provide an experimental background for the detection of novel molecular targets of icariin, which may be useful for the development of alternative therapeutic approaches for neurodegenerative conditions.

Methods {#s2}
=======

Cell Culture and Treatment {#s2_1}
--------------------------

Human neuroblastoma SK-N-MC cells (ATCC, Bethesda, MD, USA) were maintained in Minimum Essential Media (MEM, GIBCO-BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine at 37°C and 5% CO~2~. The cells were treated with 2.5 mM of Aβ 1-42 for 24 h, to induce insulin resistance ([@B8]). Aβ 1-42 was acquired from AnaSpec Inc. (San Jose, CA, USA), dissolved in 100% 1,1,1,3,3,3-hexafluoro-2-propanol, and then dried using a vacuum desiccator. Next, Aβ was resuspended in dimethylsulfoxide (DMSO) and stored at -20°C ([@B8]). Icariin (I1286) was obtained from Sigma-Aldrich, Corp. (St. Louis, MO, USA) and dissolved in DMSO. The final concentration of DMSO in the cell supernatant was 1% (v/v). To measure insulin signaling and glucose uptake, the cells were serum-starved for 6 h and then stimulated with 100 nM of insulin for 10 min.

Small Interfering RNA (siRNA) and Transfection {#s2_2}
----------------------------------------------

PTEN siRNA (\#6538) and control siRNA (\#6201) were obtained from Cell Signaling Technology (Beverly, MA, USA). Transfection of siRNAs was performed according to the manufacturer's protocol. Western blot analysis was performed to measure the transfection efficiency.

Quantitative Real-Time RT-PCR (RT-qPCR) {#s2_3}
---------------------------------------

RT-qPCR was performed as described previously ([@B10]). The primer sequences used were as follows: PTEN forward, 5′-GTCACTGCTTGTTGTTTGC-3′ and reverse, 5′-TTCTTTGTTGATAGCCTCCAC-3′; U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and reverse, 5′-CGCTTCACGAATTTGCGTGTCAT-3′. Relative gene expression was quantified by the 2^-ΔΔCt^ method and normalized to U6. All samples were analyzed in triplicates.

Adenovirus/PTEN Construction and Transduction {#s2_4}
---------------------------------------------

Adenovirus carrying the human PTEN gene (Ad/PTEN) was constructed as described previously ([@B25]). Adenoviruses encoding β-galactosidase (Ad/β-gal) were kindly provided by Dr. Xuejun Wang (The University of South Dakota Sanford School of Medicine, SD, USA). The cells were incubated in serum-free medium containing adenoviruses for 6 h, and then grown in growth medium for another 36 h. Forty-two hours after virus infection, the cells were pending for experimental study. Ad/β-gal served as a negative control. The optimal multiplicity of infection (MOI) used in the experiments was 50 ([@B36]).

Proteasome Peptidase Activity Assays {#s2_5}
------------------------------------

The chymotrypsin-like activity of the 20S proteasome in the cells was measured as described previously ([@B36]; [@B10]). Briefly, the cells were lysed with cytosolic extraction buffer (50 mM HEPES, pH 7.5, 20 mM KCl, 5 mM MgCl~2~, 2 mM ATP, 1 mM DTT, 0.025% Digitonin). The lysate was centrifuged at 10,000 × *g* for 10 min at 4°C, and the supernatants were collected. Protein concentration was determined through the bicinchoninic acid (BCA) assay. The synthetic fluorogenic peptide substrate Suc-LLVY-Amc (Boston Biochem, Cambridge, MA, USA) was used for assaying chymotrypsin-like peptidase activity. For assay specificity, 1 μM of proteasome inhibitor MG132 (S2619, Selleck, Shanghai, CN) was incubated with the extract. After 90 min of incubation at 37°C, the fluorescence intensity was read (excitation, 350 nm; emission, 440 nm) using fluorescence spectrometer (Perkin Elmer precisely LS 55, Billerica, MA, USA).

Glucose Uptake Assay {#s2_6}
--------------------

The Glucose Uptake Assay Kit (Colorimetric) (ab136955, Abcam Inc., Cambridge, MA, USA) was used to measure glucose uptake according to the manufacturer's protocol.

Western Blot Analysis {#s2_7}
---------------------

Quantification of proteins or phosphorylated proteins was performed by western blotting, as described previously ([@B36]; [@B10]). Briefly, the cells were lysed in lysis buffer (50 mM HEPES, pH 7.6, 150 mM NaCl, 1% Triton X-100, 10 mM NaF, 20 mM sodium pyrophosphate, 20 mM β-glycerol phosphate, 1 mM sodium orthovanadate, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 1 mM phenylmethanesulfonyl fluoride). The lysates were incubated on ice for 20 min and then centrifuged at 14,000 × *g* for 10 min at 4°C. The supernatants were mixed with an equal volume of 2 x SDS-PAGE loading buffer and then heated at 95°C for 10 min. The proteins were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and detected with specific antibodies.

Statistical Analysis {#s2_8}
--------------------

The data are presented as the mean ± standard deviation (SD). The differences between the groups were examined for statistical significance using analysis of variance (ANOVA), followed by the Newman--Keuls *post hoc* test. A *p*-value \<0.05 was considered statistically significant. The figures are the representative of at least four independent experiments with similar results.

Results {#s3}
=======

Icariin Improved Aβ-Induced Neuronal Insulin Resistance {#s3_1}
-------------------------------------------------------

To observe the potential effects of icariin on neuronal insulin resistance, human neuroblastoma SK-N-MC cells were serum-starved for 6 h and then treated with or without 2.5 mM of Aβ 1-42, in the presence or absence of 25, 50, or 100 μM of icariin for 24 h, followed by stimulation with or without 100 nM of insulin for 10 min. Aβ was used to induce neuronal insulin resistance *in vitro* ([@B38]; [@B16]; [@B22]; [@B31]) and insulin was administered to stimulate insulin signaling. As shown in [**Figure 1**](#f1){ref-type="fig"}, icariin treatment reversed the inhibitory effects of Aβ on insulin-stimulated phosphorylation of Akt at Thr308 and of its downstream substrate AS160 ([**Figures 1A, B**](#f1){ref-type="fig"}). To test the effects of icariin and Aβ on glucose uptake, SK-N-MC cells were serum-starved for 6 h and then treated with or without 2.5 mM of Aβ 1-42, in the presence or absence of 50 μM of icariin for 24 h, followed by stimulation with or without 100 nM of insulin for 10 min. We found that icariin treatment significantly increased 2-deoxy-D-glucose (2-DG) uptake ([**Figure 1C**](#f1){ref-type="fig"}) under stimulation with insulin, when compared with Aβ treatment alone. These results suggested that icariin treatment protected SK-N-MC cells against Aβ-induced insulin resistance.

![Icariin mitigated Aβ-induced insulin resistance in SK-N-MC cells. **(A)** Effect of icariin (ICA) on insulin (INS)-stimulated phosphorylation of Akt T308 and AS160. **(B)** Quantification of p-Akt T308 shown in **(A)**. **(C)** Effect of ICA on INS-stimulated 2-deoxy-D-glucose (2-DG) uptake. N = 4. \*\**p* \< 0.01, \*\*\**p* \< 0.001 *vs.* indicated group.](fphar-11-00880-g001){#f1}

PTEN Was Involved in Aβ-Induced Insulin Resistance {#s3_2}
--------------------------------------------------

To determine the mechanisms underlying the protective effects of icariin on Aβ-induced insulin resistance, the expression levels of key proteins involved in the regulation of Akt phosphorylation, such as IRS-1, PTEN, PDK1, and TRB3, were investigated. SK-N-MC cells were serum-starved for 6 h and then treated with or without 2.5 mM of Aβ 1-42 for 24 h. We found that Aβ 1-42 treatment significantly enhanced only PTEN protein levels ([**Figures 2A, B**](#f2){ref-type="fig"}) whereas PTEN mRNA levels remained unchanged ([**Figure 2C**](#f2){ref-type="fig"}). To confirm the role of PTEN in Aβ-induced insulin resistance, PTEN was knocked down (KD) in SK-N-MC cells by siRNA techniques. Wild-type or PTEN KD cells were treated with or without 2.5 mM of Aβ 1-42 for 24 h, followed by stimulation with or without 100 nM of insulin for 10 min. We found that PTEN depletion markedly prevented Aβ-induced reduction of insulin-stimulated Akt T308 phosphorylation ([**Figures 2D, E**](#f2){ref-type="fig"}) and glucose uptake ([**Figure 2F**](#f2){ref-type="fig"}). These results suggested that the increased PTEN levels were responsible for Aβ-induced neuronal insulin resistance *in vitro*.

![Aβ elevated PTEN protein levels in SK-N-MC cells. **(A, B)** Effect of Aβ on PTEN protein levels. **(C)** Effect of Aβ on PTEN mRNA levels. **(D)** Effect of PTEN knockdown on Aβ-induced insulin resistance. **(E)** Quantification of p-Akt T308 shown in **(D)**. **(F)** Effect of PTEN knockdown on INS-stimulated 2-deoxy-D-glucose (2-DG) uptake in Aβ-treated cells. N = 4. \*\**p* \< 0.01, \*\*\**p* \< 0.001 *vs.* indicated group; ^\#^*p* \> 0.05 *vs.* control group.](fphar-11-00880-g002){#f2}

Icariin-Induced PTEN Degradation Contributed to Its Protective Effects Against Aβ-Induced Insulin Resistance {#s3_3}
------------------------------------------------------------------------------------------------------------

To check the effects of icariin on PTEN, SK-N-MC cells were serum-starved for 6 h and then treated with or without 2.5 mM of Aβ 1-42, in the presence or absence of 50 μM of icariin for 24 h. We found that icariin treatment significantly reduced Aβ-enhanced PTEN protein levels ([**Figures 3A, B**](#f3){ref-type="fig"}). To investigate whether PTEN is a target of icariin's activity, a PTEN rescue experiment was performed, in which PTEN was overexpressed by infecting the cells with Ad/PTEN. Ad/β-gal acted as a negative control. The control or PTEN-overexpressing SK-N-MC cells were serum-starved for 6 h and then treated with or without 2.5 mM of Aβ 1-42, in the presence or absence of 50 μM of icariin for 24 h, followed by stimulation with 100 nM of insulin for 10 min. We found that the PTEN-overexpressing SK-N-MC cells displayed a reduction in insulin-stimulated Akt T308 phosphorylation ([**Figures 3C, D**](#f3){ref-type="fig"}) and glucose uptake ([**Figure 3E**](#f3){ref-type="fig"}) in response to the combined treatment with Aβ and icariin, when compared with the control cells.

![Icariin reduced the Aβ-induced elevated PTEN protein levels in SK-N-MC cells. **(A, B)** Effect of icariin (ICA) on PTEN protein levels. **(C)** Overexpression of PTEN (PTEN OE) abolished the beneficial effects of ICA on insulin signaling. **(D)** Quantification of p-Akt T308 shown in **(C)**. **(E)** Effect of PTEN OE on INS-stimulated 2-deoxy-D-glucose (2-DG) uptake in the cells co-treated with Aβ and ICA. N = 4. \*\**p* \< 0.01, \*\*\**p* \< 0.001 *vs.* indicated group.](fphar-11-00880-g003){#f3}

In addition, the results of the RT-qPCR revealed that icariin did not affect the mRNA levels of PTEN ([**Figure 4A**](#f4){ref-type="fig"}, [**Figure S1**](#SM1){ref-type="supplementary-material"}). Interestingly, Aβ treatment significantly inhibited proteasome activity, which was prevented by icariin administration ([**Figure 4B**](#f4){ref-type="fig"}). In line with this finding, we also observed that icariin administration reduced the Aβ-enhanced ubiquitination of total proteins ([**Figure 4C**](#f4){ref-type="fig"}). These findings suggested that icariin reduced PTEN protein levels *via* a proteasome-dependent mechanism. To confirm this hypothesis, SK-N-MC cells were serum-starved for 6 h, pretreated with 2 μM of proteasome inhibitor MG132 for 30 min, and then treated with or without 2.5 mM of Aβ 1-42, in the presence or absence of 50 μM of icariin for 24 h. We found that MG132 administration significantly increased PTEN protein levels, when compared with the group that received a combined treatment of Aβ and icariin ([**Figures 4D, E**](#f4){ref-type="fig"}).

![Icariin activated proteasome leading to the degradation of PTEN in SK-N-MC cells. **(A)** Effect of icariin (ICA) on PTEN mRNA levels. **(B)** Effect of ICA on the proteasome activity. **(C)** Effect of ICA on the ubiquitination of total proteins. **(D, E)** The proteasome inhibitor MG132 abolished the effect of ICA on PTEN protein levels. N = 4. \*\*\**p* \< 0.001 *vs.* indicated group; ^\#^*p* \> 0.05 *vs.* indicated group.](fphar-11-00880-g004){#f4}

Taken together, these results suggested that icariin activated the proteasome, leading to a reduction of PTEN protein levels, by which icariin exhibited its protective effects against Aβ-induced neuronal insulin resistance.

Discussion {#s4}
==========

Previous studies have demonstrated the interactions between insulin and Aβ. Insulin can inhibit Aβ aggregation, enhance Aβ degradation, and prevent Aβ-induced cellular events, such as membrane disruption and tau phosphorylation ([@B34]; [@B14]). On the other hand, Aβ has also been found to modulate insulin signaling. For example, Aβ can reduce the responsiveness to insulin in presynaptic terminals ([@B7]), decrease insulin expression in cultured astrocytes ([@B26]), impair neuronal insulin receptors ([@B38]), and induce insulin resistance in neuronal cells and peripheral cells ([@B35]; [@B16]; [@B31]). These deleterious effects of Aβ on insulin action or insulin sensitivity may be mediated by activating the JAK2/STAT3/SOCS-1 or JNK signaling pathways ([@B35]; [@B16]).

In the present study, we found that Aβ increased PTEN protein levels ([**Figures 2A, B**](#f2){ref-type="fig"}), which is consistent with previous work showing the involvement of PTEN proteins in the Aβ-induced toxicity observed in organotypic hippocampal slice cultures ([@B17]). The tumor suppressor PTEN is a phosphoinositide 3-phosphatase that serves as the main negative regulator of class I phosphoinositide-3-kinases (PI3Ks) ([@B9]). Therefore, Akt can be indirectly dephosphorylated and inactivated by PTEN. In line with this, we found that Aβ-reduced insulin-stimulated Akt phosphorylation and glucose uptake were significantly mitigated by PTEN depletion ([**Figures 2A--F**](#f2){ref-type="fig"}). Given that the mRNA levels of PTEN remained unchanged by Aβ treatment ([**Figure 2C**](#f2){ref-type="fig"}), these findings suggested that Aβ induced neuronal insulin resistance by upregulating PTEN protein levels.

In addition, we found that icariin treatment significantly suppressed Aβ-enhanced PTEN protein levels ([**Figures 3A, B**](#f3){ref-type="fig"}), but had no effect on PTEN mRNA levels ([**Figure 4A**](#f4){ref-type="fig"}, [**Figure S1**](#SM1){ref-type="supplementary-material"}). The improvement of insulin-stimulated Akt phosphorylation and glucose uptake by icariin treatment was also abolished by PTEN overexpression ([**Figures 3C--E**](#f3){ref-type="fig"}). These findings indicated that the protective effect of icariin against Aβ-induced insulin resistance was mediated by PTEN.

Some miRNAs have been shown to modulate PTEN expression at the post-transcriptional level. For example, both of miR-186 and miR-21 can negatively regulate gene expression by binding to the 3′-untranslated region (3′-UTR) of PTEN mRNAs, leading to mRNA degradation or translational repression ([@B2]; [@B5]). Interestingly, icariin can upregulate these miRNAs ([@B11]; [@B15]), suggesting a possibility of that miR-186 or miR-21 may mediate the inhibitory effects of icariin on PTEN. However, our RT-qPCR results revealed that neither Aβ nor icariin affected the expression levels of miR-186 and miR-21 in SK-N-MC cells (data not shown). In addition, our results showed that PTEN mRNA levels did not significantly change following treatment with Aβ or icariin ([**Figures 2C**](#f2){ref-type="fig"} and [**4A**](#f4){ref-type="fig"}, [**Figure S1**](#SM1){ref-type="supplementary-material"}). These findings indicated that the inhibitory effects of icariin on PTEN were independent of miRNAs.

It has been demonstrated that the ubiquitin-proteasome system plays a critical role in the degradation of PTEN protein ([@B32]). One reason for the increased PTEN protein levels induced by Aβ may be its inhibitory effect on proteasome activity ([@B27]). Indeed, we found that Aβ treatment significantly reduced proteasome activity in SK-N-MC cells ([**Figure 4B**](#f4){ref-type="fig"}). Icariin has been proven to activate the proteasome ([@B39]; [@B10]). As an inhibitor of phosphodiesterase type 5 (PDE5) ([@B33]; [@B20]), icariin indirectly stimulates proteasome activity by activating the cGMP/PKG pathway ([@B21]). In addition, icariin can also directly increase the expression levels of some proteasome subunits, such as proteasome subunit-alpha type 6 and type 2, and reverse the inhibitory effects of the proteasome inhibitor epoxomicin on proteasome activity ([@B39]). In the present study, we found that icariin administration significantly protected SK-N-MC cells against Aβ-suppressed proteasome activity, and reduced total protein ubiquitination ([**Figures 4B, C**](#f4){ref-type="fig"}). Furthermore, the inhibition of proteasome activity by its specific inhibitor MG132 abolished the effects of icariin on PTEN in Aβ-treated cells ([**Figures 4D, E**](#f4){ref-type="fig"}). These findings suggested that icariin activated the proteasome, leading to PTEN degradation.

In summary, icariin exposure improved Aβ-induced neuronal insulin resistance, which is mediated by a proteasome-associated PTEN degradation. These findings suggest that icariin might be a novel therapeutic agent for the treatment of neurodegenerative diseases, such as the PD and the AD. However, further studies are needed to elucidate the mechanisms by which icariin regulates insulin signaling in the CNS *in vivo*.

Limitation {#s4_1}
----------

In the present study, we described the molecular mechanisms by which icariin mitigated Aβ-induced neuronal insulin resistance. However, the majority of the results were based on Aβ-treated SK-N-MC cells, which represent an *in vitro* model of uncertain relevance to AD. In addition, the insulin concentration used in the performed experiments was higher than the physiological one. The concentrations of icariin were also relatively high. Therefore, further studies are necessary to obtain more potent derivatives of icariin, as well as to provide further *in vivo* evidence in experimental settings closer to clinical reality.
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